The Wnt-β-catenin/TCF4 signaling pathway was found to be abnormally activated in colon and breast cancers and associated with a poor prognosis [40], suggesting the potential of DDX5 as a valuable diagnostic and prognostic marker and potential therapeutic target for many tumors. Here, DDX5 is linked to breast carcinoma.